Global Neonatal Seizures Drugs Market, By Type (Tonic Seizures, Clonic and Myoclonic Seizures, Non Paroxysmal Repetitive Behaviours), Drug (Dilantin, Phenobarbital, Other), Dosage (Tablets, Injection, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Due to the limited evidence available to help decide the appropriate usage of drugs for children of all ages with varied forms of epilepsy, doctors confront unique problems while treating children with epilepsy. However, progress has recently been made in understanding how antiepileptic medicines (AEDs) can be used to treat newborn seizures and infantile spasms, which are seizure disorders that occur in the first year of life. The efficacy of AEDs in treating these illnesses has been disputed, and predicting the fate of these problems for each kid has been challenging, so any advancement is welcome.
Data Bridge Market Research analyses that the neonatal seizures drugs? market was valued at USD 222.5 million in 2021 and is expected to reach USD 290.73 million by 2029, registering a CAGR of 3.40% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Tonic Seizures, Clonic and Myoclonic Seizures, Non Paroxysmal Repetitive Behaviours), Drug (Dilantin, Phenobarbital, Other), Dosage (Tablets, Injection, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (US), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (US), Johnson & Johnson Private Limited (US), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)
|
|
Market Opportunities
|
|
Market Definition
Seizures in neonates are aberrant electrical discharges in the central nervous system that typically appear as stereotyped muscle activity or autonomic abnormalities. Electroencephalography confirms the diagnosis, and further testing for reasons is recommended. Treatment is determined by the underlying cause. Seizures affect up to 1.4 percent of full-term new-borns and 20% of premature infants. Seizures could be a sign of a significant neonatal condition that has to be evaluated right away. The lack of myelination and insufficient creation of dendrites and synapses in neonates prevents generalization of electrical activity, hence most neonatal seizures are focal.
Neonatal Seizures Drugs Market Dynamics
Drivers
- Increasing prevalence of hypoxia-ischemia
The rising prevalence of hypoxia-ischemia is anticipated to influence the neonatal seizures drugs? market's growth. The most prevalent cause of neonatal seizures is hypoxia-ischemia, which can occur before, during, or after delivery. Seizures of this nature can be severe and difficult to treat, but they usually subside after 3 to 4 days. Seizures may be less severe when new-born hypoxia is treated with therapeutic hypothermia (typically whole-body chilling), although they may recur upon rewarming.
- Rising incidences of neonatal infections
The increasing incidences of neonatal infections is expected to flourish the market's growth rate during the forecast period of 2022-2029. Seizures can occur as a result of neonatal infections including meningitis and sepsis; in these cases, seizures are usually accompanied by other symptoms and signs. In neonates, group B streptococci and gram-negative bacteria are the most common causes of infection. Seizures can also be caused by encephalitis caused by the cytomegalovirus, herpes simplex virus, rubella virus, Treponema pallidum, Toxoplasma gondii, or Zika virus.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the neonatal seizures drugs? market. Additionally, rising healthcare expenditure and changing lifestyle of people will result in the expansion of neonatal seizures drugs? market. Along with this, rising prevalence rate of chronic disease such as thyroid, diabetes, and kidney disease, and favourable reimbursement policies will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the neonatal seizures drugs? market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of neonatal seizures drugs during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the neonatal seizures drugs? market. Additionally, the side effects of neonatal seizures drugs? will act as market restrain and further impede the market's growth rate during the forecast period of 2022-2029.
This neonatal seizures drugs? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neonatal seizures drugs? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Seizures in new-borns are a common neurological emergency. In terms new-borns, the incidence has been reported to range from 1 to 5.5 per 1000 live births, with greater rates recorded in preterm infants. In the United States, the incidence is estimated to be between 80 and 120 instances per 100,000 new-borns per year.
Neonatal seizures drugs? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Neonatal Seizures Drugs Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations, resulting from multiple precautionary lockdowns and other limitations imposed by governments all over the world. The neonatal seizures drugs market was no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors were likely to have a negative impact on the neonatal seizures drugs market's revenue trajectory. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. As a result, the market is projected to stabilize in the future.
Global Neonatal Seizures Drugs Market Scope
The neonatal seizures drugs? market is segmented on the basis of type, drug, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Tonic Seizures
- Clonic and Myoclonic Seizures
- Non Paroxysmal Repetitive Behaviours
Drug
- Dilantin
- Phenobarbital
- Other
Dosage
- Injection
- Tablets
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Neonatal Seizures Drugs Market Regional Analysis/Insights
The neonatal seizures drugs? market is analysed and market size insights and trends are provided by country, type, drug, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the neonatal seizures drugs? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the neonatal seizures drugs? market because of the rising level of investment on research and development activities in this region. Additionally, the growing presence of major key players and well-established healthcare infrastructure will further propel themarket's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to rising healthcare expenditure and improvements in healthcare infrastructure in this region. Also, surging prevalence of kidney diseases, thyroid and liver disorders and the number of generic medications will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Neonatal Seizures Drugs Market Share Analysis
The neonatal seizures drugs? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neonatal seizures drugs? market.
Some of the major players operating in the neonatal seizures drugs? market are:
- Merck KGaA (Germany)
- Eisai Co., Ltd. (Japan)
- AstraZeneca (UK)
- Sanofi (France)
- Novartis AG (Switzerland)
- Abbott (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- WOCKHARDT (Mumbai)
- Novo Nordisk A/S (Denmark)
- Glenmark Pharmaceuticals Limited (India)
- Cipla Inc. (US)
- Bausch Health Companies Inc. (Canada)
- Otsuka America Pharmaceutical, Inc. (US)
- Johnson & Johnson Private Limited (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Sumitomo Corporation (Japan)
- Biocon (India)
SKU-